trial · primary record
Copanlisib
Chronic Lymphocytic Leukemia
| Phase | Phase 1 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 27 |
| Primary completion | 2027-10-07 |
| Primary endpoint | Incidence of dose-limiting toxicities of copanlisib in combination with nivolumab |
| Registry ID | NCT03884998 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:35:12.215Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03884998
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.